Clinical trial
Initial Study of Rituximab to Treat Primary Biliary Cirrhosis
NCT00364819 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00364819 |
|---|---|
| Title | Initial Study of Rituximab to Treat Primary Biliary Cirrhosis |
| Official title | Effects of Rituximab (Rituxan) on B Cell and AMA Response in Patients With Primary Biliary Cirrhosis |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Primary Biliary Cirrhosis |
| Intervention type | Drug |
| Interventions | rituximab |
| Enrollment | 6 |
| Start date | Jan 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Aug 16, 2006 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: